Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can blocking a hunger receptor boost weight loss? small study investigates

NCT ID NCT07171723

Knowledge-focused Sponsor: University Hospital, Gentofte, Copenhagen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at how blocking the ghrelin receptor—a key hunger signal—affects appetite in people with obesity who are already taking semaglutide (a GLP-1 drug). Researchers will give 24 participants either LEAP2 (a natural hormone that blocks ghrelin) or a placebo during two visits, then measure food intake, hunger feelings, and metabolism. The goal is not to test a new treatment, but to better understand how appetite systems work together.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LEAP2 (a natural hormone that blocks hunger signals)
What this could lead to
If successful, this study could help scientists understand how different appetite systems interact, potentially leading to better obesity treatments.
What could go wrong
This is a very small, early-phase trial (24 people) that is not testing a new treatment—it is only measuring short-term effects. Results may not lead to any new therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Feb 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 65 years old * Body mass index (BMI) above ≥ 25 kg/m2 * Ongoing semaglutide treatment with a stable dose of ≥ 1 mg once weekly for a minimum of 3 months prior to inclusion * Weight stability, defined as a maximum variation of ±3% between the highest and lowest recorded body weight during the 3 months prior to inclusion. * Informed oral and written consent Exclusion Criteria: * Anaemia * Alanine aminotransferase (ALAT) \> 2 times normal value * History of hepatobiliary and/or gastrointestinal disorder * Kidney disease (serum creatinine above normal range and/or urine albumin-creatinine ratio 30mg/g confirmed with two measurements) * Any ongoing medication that investigator evaluates would interfere with study participation * Any physical or psychological condition that investigators evaluate would interfere with study participation including any acute or chronic illnesses. * Regular tobacco smoking and/or use of other nicotine products * Glycated haemoglobin HbA1c \> 48 and/or type 1 or type 2 diabetes medical treatment * Women of childbearing potential who are not using effective contraception * Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity & overweight are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity & overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Center for Clinical Metabolic Research, Gentofte Hospital

    RECRUITING

    Hellerup, 2900, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.